Glaukos® is creating a new class of micro-bypass therapies to achieve sustainable, target intraocular pressures through the restoration of physiologic outflow, reduce the challenges and risks of glaucoma management associated with traditional therapies, and aid in the preservation of vision.
Glaukos has more than 35 employees who have extensive expertise in the ophthalmic medical device and pharmaceutical industries. The leadership team is comprised of ophthalmic device and pharmaceutical executives who have over 100 years of cumulative experience in eye care. more